Subscribe to Search results

Professor Sir Michael Rawlins stated that FDA approval was given if the licensing body had found it was appropriate and therefore it carried weight to the product.

Published on:

Professor Sir Michael Rawlins stated in his oral evidence that Dr Galbraith's May 1983 letter and paper should have been provided to the CSM(B).

Published on:

Professor Sir Michael Rawlins (CSM) stated in his oral evidence that if they had known AIDs was caused by a virus and how donors were pooled in the US, they would have acted differently regarding the importation of commercial factor concentrates.

Published on:

At a meeting of the Blood Products Advisory Committee, Dr Michael Rodell (Armour) indicated that it was clear that pools might have been contaminated. He also stated that persons who were paid for their plasma had it collected 40 to 60 times per year, on average.

Published on:

Professor Bloom wrote to Armour to express concerns that concentrate prepared from plasma collected before March 24 might be preferentially exported from the USA.

Published on:

In a letter, K.W FItch (Armour) stated that Armour had not preferentially exported plasma stocks out of the USA which had been produced from plasma collected prior to the FDA ruling.

Published on:

Dr Walford asked Dr Fowler of Medicines Division whether the supply of blood comprising pre-March plasma could be resisted.

Published on:

Dr Walford considered it possible that concentrates made from the "safer" plasma might be retained for use in the US whilst those older stocks were dumped on export markets such as the UK. Dr Walford also asked if there was any way, perhaps by new labelling requirements to prevent this.

Published on:

In a letter, Dr Oliver suggested a meeting to discuss blood product supplies and stated that any blood products imported from USA would ideally be made from plasma collected after March 1983.

Published on:

At a DHSS meeting regarding AIDs it was stated that new legal restrictions to prevent the dumping of pre-March '83 plasma would have significant practical difficulties.

Published on:

An information sheet about AIDS prepared by Dr Diana Walford was provided to John Patten.

Published on:

An information sheet about AIDS prepared by Dr Diana Walford was provided to Lord Glenarthur.

Published on:

In an information sheet about AIDS it was stated that the DHSS Medicines and Supply Divisions were endeavouring to ensure that there would be no "dumping" of high-risk plasma products on the UK market.

Published on:

A letter from Lord Glenarthur contemplated that future blood product supplies for the UK would not all be manufactured from pre-March 1983 plasma.

Published on:

C Wrigglesworth requested Dr Walford's views on whether any action was required in relation to the stocks of pre-March 1983 material and suggested there was a conflict between the result of the FDA meeting and the 13 July CSM(B) recommendation.

Published on:

In a memo, Dr Walford stated Dr Smith had "carefully worded [the] recommendation" of the CSM paper and "that supply of material must take precedence over [the] implementation [of CSM(B)'s recommendation]."

Published on:

An internal Armour memo suggested it was "vitally important" that Armour sell the products manufactured from plasma collected prior to the March 1983 FDA memorandum as quickly as possible.

Published on:

Christopher Bishop stated in his oral evidence that Armour had no qualms internally about disposing of or selling pre-March 1983 product in the UK.

Published on:

In a memo to Dr Walford, Mr Wrigglesworth (DHSS) queried whether further action was required on pre-March 1983 blood products as such products continued to be used in the USA.

Published on:

Lord Glenarthur wrote to Clive Jenkins, stating "there is no conclusive evidence that AIDS is transmitted through blood products. Nevertheless we are taking all practicable measures to reduce any possible risks to recipients of blood and blood products".

Published on: